Skip to main content

Loberg Michael D's Form 4 filing

IGM Biosciences, Inc. (IGMS) · filed Sep 29, 2022

Accession no.
0001209191-22-051559
Filed
Sep 29, 2022
Trade date
Jul 18-Sep 28, 2022
Filing delay
73 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market purchases total $139.6K. It was filed 73 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Loberg Michael DCIK 0001233414Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 18, 2022Common StockGGiftDisposed−533$0.00$00Direct
Jul 18, 2022Common StockGGiftAcquired+533$0.00$022,805Indirect
Sep 27, 2022Common StockPPurchaseAcquired+507$19.99F2+$10,134.9323,312Indirect
Sep 28, 2022Common StockPPurchaseAcquired+6,172$20.97F3+$129,426.8429,484Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $19.94 to $20.00. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate purchase price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $20.72 to $21.00. The price reported above reflects the weighted average purchase price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate purchase price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)